Source: Health Products Regulatory Authority (ZA) Revision Year: 2022 Publisher: RANBAXY PHARMACEUTICALS (PTY) LTD, 14 LAUTRE ROAD, STORMILL EXT. 1, ROODEPOORT, 1724, SOUTH AFRICA
SEDABARB.
| Pharmaceutical Form |
|---|
|
Tablet. White normal biconvex tablet, with a breakline on one side, 5,5 mm in diameter. |
Each tablet contains:
Phenobarbitone 30 mg
Contains sugar: Lactose monohydrate 17,9 mg per tablet.
For full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Phenobarbital |
Phenobarbital has sedative effects and has some protective action against all varieties of human partial and generalised epilepsy, with the exception of absence seizures. Phenobarbital is also effective in preventing seizures in the corresponding experimental animal models of epilepsy. |
| List of Excipients |
|---|
|
Flowlac 100 |
Amber PVC containers of 100, 500, 1000 and 5000 tablets.
White polypropylene securitainers of 42, 100 and 1000 tablets.
Patient ready packs of different pack sizes.
RANBAXY PHARMACEUTICALS (PTY) LTD, 14 LAUTRE ROAD, STORMILL EXT. 1, ROODEPOORT, 1724, SOUTH AFRICA
E/2.3/107 (South Africa)
19 June 1974
| Drug | Countries | |
|---|---|---|
| SEDABARB | South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
